Skip to main content
. 2018 Jun 30;9:2447. doi: 10.1038/s41467-018-04907-0

Fig. 1.

Fig. 1

Survival outcomes in gastric cancer patients with different signet-ring cell frequency (2006–2012). Survival curves of patients among the non-SRCC group (N = 837), con-SRCC group (N = 522), and SRCC group (N = 345) were illustrated in all patients (a), and stages III/IV (b). Impact of chemotherapy introduction on survival was also illustrated separately in terms of SRCC content in all patients (c), and stage III/IV (d)